ampliphi biosciences

kennt wer die aktie hat einige phase 3 produkte biotech.

danke für eure infos

messages.finance.yahoo.com/mb/APHB.PK

ist sehr volatil mm schieben hin und her alle warten auf news.

lasst euch nicht verunsichern meistens zwischen 10000 und 30000 stück am tag.

und dann müssen die wieder covern meistens anfang des jahres april mai geht schon seit 2-3 jahren so. dann 2mio am tag.

fällt dann wieder mit niedrigem volumen mit gelegntlichen upps. usw mal sehen wann die news dieses spielchen durchbrechen.

mfg

Genzyme AAV success-Ampliphi's AAVs?      1-Mar-12 02:39 pm    
I noticed that last month Genzyme released this rather good news about a Phase 1/2 clinical trial where the subjects' vision was successfully improved with the aid of AAV vectors/gene therapy:

www.medscape.com/viewarticle/7582...

Remember that in 2009 Ampliphi (then Targeted Genetics) sold a load of AAV patents and technology to Genzyme:

www.in-pharmatechnologist.com/Pro...

And that Ampliphi will benefit as follows:

www.ampliphibio.com/index.php/par...

"Under the collaboration, AmpliPhi Biosciences will receive revenue from Genzyme in the event that Genzyme sublicenses the acquired intellectual property within specified time periods, and will receive royalties in the event of commercial sales of products containing AAV vectors covered by the acquired intellectual property."

Question is, are these AAV vectors Ampliphi's?

The possibilities here are yet another reason why imho Ampliphi's valuation is ludicrously low at present given it already effectively has two products ready to start Phase 3 trials and has lots of cash available, equivalent to much of its market cap.

Nice work!

Last December I was hunting for information on Targeted Genetics’ Choroideraemia Clinical Trials - NCT00643747.

Here's the link to my post and the replies:

messages.finance.yahoo.com/Stocks...

There was some success with this process (view the video for a look at ). At this point Ampliphi hasn't come forth with and clarity around ownership or trials status and it's really about time stockholders are updated.

See any info in your research, please post. Thanks in advance.

New interview with Ampliphi     26-Mar-12 02:41 am    
www.eurekalert.org/pub_releases/2...

"Public release date: 25-Mar-2012

Using viruses to beat superbugs
Viruses that can target and destroy bacteria have the potential to be an effective strategy for tackling hard-to-treat bacterial infections. The development of such novel therapies is being accelerated in response to growing antibiotic resistance, says Dr David Harper at the Society for General Microbiology's Spring Conference in Dublin.

Bacteriophages are viruses that can infect bacteria and multiply within them, breaking down the cell and destroying the bacteria - amplifying themselves in the process to deal with more bacteria. They are found everywhere including in river water, soil, sewage and on the human body. Soon after their initial discovery in 1915, bacteriophages were investigated as antibacterial therapeutic agents. A limited understanding of their mode of action meant early work was often unsuccessful and with the advent of the chemical antibiotic era, bacteriophages were passed over as therapeutics.

Dr Harper, Chief Scientific Officer at AmpliPhi Bioscience in Bedfordshire explains why bacteriophages are being revisited as antibacterial agents. "Each bacteriophage is highly specific to a certain type of bacteria and needs the right bacterial host cell in order to multiply. The more bacterial targets there are, the quicker they grow by killing the host cells. Therefore it seems very likely that infections harbouring high numbers of bacteria will benefit most from bacteriophage therapy – for example chronically infected ears, lungs and wounds," he said. "For these types of infection, only a tiny dose of the virus is needed - as small as one thousandth of a millionth of a gram. This can usually be administered directly to the site of infection in a spray, drops or a cream. The major advantage to bacteriophages is that they don't infect human cells so seem likely to be very safe to use."

Increasing resistance to antibiotics has meant that bacterial infections are becoming more and more difficult to treat. With fewer antibiotics available to treat drug-resistant infections, research into bacteriophage therapy has been accelerated. "The rate of new antibiotics coming onto the market does not match the rate of increasing drug-resistance. The need for new approaches to counter such high resistance is both urgent and vital. New approaches will save lives," stressed Dr Harper.

Clinical trials for bacteriophage therapy are now underway. The first clinical trial for safety was reported in 2005 and the results demonstrating the effectiveness of bacteriophage therapy were published in 2009. This clinical trial was conducted by AmpliPhi. The company is planning further clinical trials in conditions where existing antibacterial therapies are not able to help. "With the results of further clinical trials, once regulatory issues are overcome and future investment secured in this area of research, this should lead to the development of novel products suitable for widespread use to tackle bacterial diseases and overcome antibiotic resistance", said Dr Harper."

messages.finance.yahoo.com/Stocks_(A_to_Z)/...;tof=1&frt=2

finance.yahoo.com/mb/APHB/

mfg

finance.yahoo.com/mbview/threadview/...172e5d5a&tls=la,d,0

mfg

finance.yahoo.com/mbview/threadview/...4177f884&tls=la,d,0

finance.yahoo.com/news/...ollaboration-intrexon-121100056.html


p25162 •

Approx. 100,000,000 mil shares, approx. $15 mil market cap., at $0.15.

approx. $15 mil. Market Cap as of today.Based on the press release we just got the updated outstanding share count and Market Cap. Approx. 100,000,000 mil shares,.

I think a fair market cap range today should be at a minimum of $30 mil to $60 mil, or in the $0.30 to $0.60 share price range. Once the Glybera milestone payment is announced (already happened), and royalties revenues start ccming in Q.3 , and a CF Trial partner funded trial announcement the stock could trade in the $1 to $1.50 range.

I'm very encourage by Intrexon novel approach match with APHB phage development.
----------------------------------------
AmpliPhi will issue to Intrexon 24,000,000 shares of its common stock (representing approximately 26% of Ampliphi’s outstanding shares after the issuance). The ECC also includes the potential for development milestones that are payable in equity or cash. In addition, AmpliPhi will pay Intrexon royalties on the net sales of products developed under the ECC Less Less

More royalties for APHB?

News today - Uniqure are developing a gene therapy for Huntingdons Disease using their AAV platform (presumably derived from APHB/TGEN's technology) and have now received a 2.5m euro grant.


"uniQure B.V., a leader in the field of human gene therapy, today announced
that with its consortium partners it is to receive a EUR 2.5 million Eurostars grant to develop an RNA interference (RNAi) gene therapy for Huntington's disease. The consortium is a pan-European collaboration consisting of uniQure as the coordinator, Lausanne University Hospital, Switzerland, University Medical Center Gottingen, Germany, and Maria Curie-Skłodowska University, Poland.

The program's aim is to develop a gene therapy for the treatment of Huntington's
disease (HD), a rare and devastating neurodegenerative disease caused by
mutations in the Huntingtin (Htt) gene.

Good PR in the Sunday Times

Huge article in yesterday's Sunday Times in London about routine infections becoming life-threatening, overuse of antibiotics etc.

It talks about the few methods of stopping superbugs - and specifically says:

"■ Invest in research into new treatments and drugs, such as ‘bacteriophage’ viruses that kill bacteria and can be used to sterilise dressings"

APHB are the world leaders in bacteriophages. IMO its time is about to come.

And APHB are recruiting for a Senior Scientist - hopefully this is good news and a sign of confidence:

"AmpliPhi Biosciences is seeking a Senior Scientist to work in the UK laboratory. The post holder will be part of a global team developing bacteriophages (phages) for human and animal antibacterial medicines. We seek a candidate who is motivated by our mission to develop novel healthcare products....

....The post will be based at Colworth Science Park, Sharnbrook, Bedfordshire. Travel to company sites in Sydney, Australia and Richmond, USA may be required."

l

Big news today - agreement with US Army

News just out....

"AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections
July 01, 2013

AmpliPhi BioSciences Corporation (OTC:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).

The CRADA will focus on developing and commercializing bacteriophage therapeutics to treat Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa infections. The increasing prevalence of antibiotic-resistant bacteria poses a serious threat to public health and military personnel and is a major problem in hospitals and clinics around the world. The initial indication will be wounds and skin infections from S aureus, which is the leading pathogen in healthcare-associated infections in the United States as a whole, accounting for 30.4% of surgical site infections.

AmpliPhi will retain global regulatory ownership and commercial rights to all products developed as a result of the agreement. USAMRMC will gain access rights to any products developed. WRAIR will be responsible for cGMP production of the lead Staphylococcus product, AmpliPhage-002 for Phase 1 and 2 clinical trials at its Bioproduction Facility. Further details of the agreement including financial terms were not disclosed.

Philip J. Young, CEO of AmpliPhi, said: “This collaboration is a significant partnership for our company. It combines AmpliPhi’s expertise in the discovery and development of bacteriophage-based therapies with the US Army’s scientific and clinical research for the development of phage therapies for treatment of bacterial infections. It will serve to expedite the development, testing and approval of new treatment modalities.

In conjunction with this financing transaction, Julian P. Kirk, Managing Director of Third Security, LLC, will join AmpliPhi’s Board of Directors. Mr. Jeremy Curnock Cook, Chairman of the Board of Directors, commented, "The addition of Julian is an important milestone in the continued evolution of AmpliPhi. We are excited to be welcoming him to the board and look forward to his guidance through the continued strategic, operational and financial growth of the company." In addition, Dr. Caroline Williams and Mr. Anthony Gellert have resigned from the Board of Directors. “We thank Caroline and Tony for their service and contribution to the progress of the Company,” added Mr. Curnock Cook.

Griffin Securities, Inc. served as lead placement agent and Philip Capital served as co-placement agent to AmpliPhi Biosciences, Inc. in connection with the transaction.

ENDS

About AmpliPhi BioSciences Corp.

AmpliPhi BioSciences Corp. is a biotechnology company focused on the development and commercialization of novel bacteriophage-based therapeutics for difficult to treat infectious diseases, which includes treatments for bacterial infections associated with Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus Aureus (MRSA), Escherichia coli (E. coli), and Clostridium difficile (C. difficile). AmpliPhi was created in 2011 through the merger of BioControl Ltd with Targeted Genetics Inc. and subsequent combination with Special Phage Services in 2012. The Company is US-headquartered in Richmond, Virginia and has operations in Colworth, UK and Sydney, Australia. For more information, visit www.ampliphibio.com

More information about the company is available at www.ampliphibio.com

Forward-looking statements

Statements in this press release about the potential use of bacteriophages to treat bacterial infections and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that such therapies may not be successfully developed, will require extensive and expensive pre-clinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency.

Excellent news today re Glybera

"July 09, 2013 08:00 ET

uniQure Signs EU Commercialization Agreement With Chiesi Farmaceutici for First Approved Gene Therapy Treatment, and Announces EUR 45 Million (USD 58 Million) in Equity and Collaboration Financing

Partnership With Chiesi Farmaceutici for Commercialization of Glybera and Co-Development of Hemophilia B Gene Therapy in Europe and Certain Other Territories; Conversion of Outstanding Convertible Debt by Coller Capital and Other Investors

AMSTERDAM, THE NETHERLANDS--(Marketwired - Jul 9, 2013) - uniQure B.V., a leader in human gene therapy, today announced it has signed collaboration agreements with Chiesi Famaceutici SpA for the commercialization of Glybera, the first gene therapy to receive regulatory approval in Europe, as well as the co-development of a gene therapy for hemophilia B. In connection with this transaction, uniQure has received EUR 17 million (USD 21.8 million) in collaboration financing and EUR 14 million (USD 18 million) in equity financing from Chiesi, and has converted into equity the previously announced EUR 14.1 million (USD 18.1 million) investment led by Coller Capital (London, UK) with participation by existing investors......

.....
The investment from Coller Capital, supplemented by our existing investors, allows us to continue apace with the development of what we believe is the richest and most advanced gene therapy pipeline in the industry. In the next 12-18 months, we anticipate clarifying the path toward an FDA filing for Glybera in the US, reporting results from a Phase I/II study in acute intermittent porphyria, and starting at least two Phase I/II studies for additional pipeline programs."  

New Edison research just out

There's a new catch-up note out from Edison - with a first full note to follow:

Extract:

"Investment summary: Turning a fresh p(h)age

A $7m private placement with RA Capital and Third Security, and a research collaboration with the US army, provide AmpliPhi with fresh impetus in its development of bacteriophages. These deals build on the purchase of Special Phage Services (SPS) last year and a recent strategic collaboration with Intrexon. AmpliPhi is the only company to have completed a controlled Phase I/II study with bacteriophages (naturally-occurring viruses that kill bacteria). The next steps towards technology validation are Phase I and II studies with the US army in 2014 in skin infections due to S Aureus, and a Phase II study to treat Pseudomonas infections in cystic fibrosis (CF)."

"Valuation: Modest $25m EV

We estimate AmpliPhi’s EV at $25m, based on 197m total shares now outstanding and $6.85m net cash at end-Q213. We view this as modest, particularly with regard to the CF opportunity. We will initiate full coverage of AmpliPhi in due course."  

investorshub.advfn.com/boards/read_msg.aspx?message_id=89629339

mfg

Hier gabs aber heavy dilution,hm !

wie meinst du das? beobachte die firma schon einige zeit aber diesen volumen anstieg in den letzten wochen bzw die vermehrten nachrichten, habe ich noch nicht gesehn. deren produkt pipeline sieht sehr vielversprechend aus. der anstieg müsste nächste woche nachhaltig bis 0,40 0,50 weitergehen ansonsten könnte es mit kleinen umsätzen die nächsten wochen wieder runtergedrückt werden. mal sehen wie es am montag weitergeht.

mfg

zu gehn

geil los komm da geht noch was!!!!!

die wird doch nicht...

fällt dann könnte es interessant werden. andererseits wäre ein rücksetzer auch möglich nach der rallye. dass volumen könnte höher sein. lass mich überraschen.

mfg

ein schönes W werden?!! hält sich bei mittlerem volumen recht gut. hoffe es geht diese woche richtung 0,7$.

finance.yahoo.com/news/...teriophages-treatment-040100126.html

interessantes chartbild!! umsätze noch niedrig!

mfg

Fabulous news update L. Thanks.
The data to date suggests that the Phase 2b results in approx.18 months could be signficant enough to bring the MYDICAR, FDA Orphan status, to market, in 2015, without going to Phase 3 first.
Last weeks press release could be enough to push APHB to the $1 plus trading range. The upside annual royalty stream due to APHB for MYDICAR is well in excess of $100 mil. a year. Apply that multiplier/valuation to today's market cap. ($90 mil or so) and APHB would be trading many times today's current valuation, and that''s just based on MYDICAR, not Glybera or the significant upside of the biophage developing franchise. Plus US Army, Intrexon, and pending CF partner annoucement anytime now

mfg

The securities offered in this private placement transaction have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of a registration rights agreement entered into with the investors, the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock sold in the offering. Any offering of the Company’s securities under the resale registration statement referred to above will be made only by means of a prospectus.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

About AmpliPhi BioSciences

AmpliPhi BioSciences Corporation (APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based therapeutics. The Company’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (XON), the U.S. Army and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies. The Company is US-headquartered in Richmond, Virginia and has operations in Colworth, UK and Sydney, Australia. For more information, visit www.ampliphibio.com.

About Bacteriophages

Bacteriophages are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophages are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defence for bacteria, contributing to antibiotic resistance. Bacteriophages are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

Forward Looking Statements

To the extent that this press release discusses expectations or otherwise makes statements about the future, such statements are forward-looking and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made, including without limitation the risk that bacteriophage-based therapies may not be successfully developed, will require extensive and expensive pre-clinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency. The Company does not undertake any obligation to update any forward-looking statements to reflect future events or circumstances after the date of such statements.  

p25162 • 7 hours ago

   

NYSE listing pending, SEC filing, 12-6-2013, 110,528,505 shares common stock outstanding

Recent SEC filing available to all coincided with $18 mil. stock sale, investor road show, APHB filed consolidated financials as of Sept 2013.. Ampliphi is reincorporating from a WA corporation to a Delaware corp. More importantly APHB appears to be seeking a New York Stock exchange listing to coincide with a reverse split (need to be above $4). This is very positive news for APHB shareholders. More liquidity, institutional investors & media exposure, etc. APHB has approx. $21 mil. is Stockholder equity as of today.

As of December 6, 2013, there were 110,528,505 shares of common stock outstanding and 8,859,978 shares of Series B Convertible Preferred Stock outstanding.

As of December 6, 2013, there were outstanding warrants to purchase the following shares of our capital stock:
Description # of shares subject to such Warrants Weighted-average exercise price of such Warrants
Common Stock 36,780,385 $ 0.15

As December 6, 2013, there were 25,721,000, shares of common stock subject to outstanding options.

On December 16, 2013, we entered into subscription agreements to issue an aggregate amount of approximately 72,003,000 shares of common stock for an aggregate purchase price of approximately $18 million as part of a private placement.

mfg

thefourthlaw • 5 hours ago

   

Richmond BizSense Article

With enough PR, maybe that split can be less than 1:10...

~~~~~~~~~~~~~~~~~
Firm’s pitch comes through loud and clear
MICHAEL SCHWARTZ JANUARY 2, 2014 0

Two capital raises in the past six months have an upstart local biotech firm feeling flush.

AmpliPhi Biosciences brought in $18 million in fresh cash in December. That followed $7 million it raised over the summer. The combined funds give the Glen Allen-based firm the firepower it needs to continue development of its bacteria-killing products into 2015.

“It’s giant,” Young said of the market potential for their products. “The global antibiotic market is estimated to top $40 billion by 2015. The numbers are huge.”

If and when they comes to market, AmpliPhi’s products would be delivered to patients in a variety of forms, including pills, inhalants and topical and intravenous applications.

The company will look to do clinical trials in 2014, although Young said patience is a virtue in the biotech industry. Getting a product to market is a long and complicated process of trial and error and regulatory red tape.

“You’ve got to be patient, but getting it going is exciting,” he said.

Its stock, which trades on the OTC Bulletin Board under the ticker symbol APHB, finished 2013 at $0.50 per share. The company hopes to move its stock to the New York Stock Exchange in the first quarter of 2014, Young said.

The two recent capital raises should last at least 18 months or so, but Young said AmpliPhi would continue its roadshow to get in front of investors.

“We’re never done,” he said. “I am very happy we got this money. But we’re never done meeting investors and talking to investors.


mfg

Nice find and post. To answer your earlier question about the reverse split ratio, I think it will be a minimum of what ever ratio gets APHB to at least $5 a share ($4 is required on NYSE for the listing) to attract institutional and mutual fund investors. Hopefully APHB is trading in the $1 plus range with today's share count by the time it sets the reverse split level ratio.

Buying APHB share today is like getting a Pre-IPO shares in a sense since APHB is not well known to the Street; however, once the NYSE listing is even announced, the exposure will attract $$ buyer based on the significant market potential and APHB leadership in Phage. That doesn't even consider their legacy royalty assets the will start producing revenue (Glybera) any day now. MYDICAR is even more significant even in the 3% to 5% new royalty range, potentially in the 2016 timeframe.

I like the fact that Phil is excited to continue spreading the Ampliphi word (their leadership position & addressable market) to new investors with road shows, and has positioned the company for NYSE listing. in Q.1/2014

Broadfin Healthcare Master Fund, Ltd. (Hedge) buys 14 Million APHB shares

Fantastic news for APHB on the Investor front with the recent hedge funds ($500 mil. under mgmt ) SEC filing,SC 13G on 1-3-2014, stating their recent 14 million APHB share purchase,, representing 7.67% of common. The share purchase price wasn't listed in the SEC filing.

I like the fact that APHB has raised an est. $30 mil. or so even in less than 6 months, even before they list on the NYSE in the coming months. It's highly likely we'll see significant upward movement in the share price before the NYSE listing with buyers getting in beforehand. Any significant Buy volume will move the stock up significantly based on the average daily trading volume. Less

scheint als könnte es wieder richting 1 $ gehen.

mfg

Mobile health technology company iSonea Limited was another standout performer for the biotech sector, boasting a share price increase of 379% for the calendar year to lift its market cap to $88 million.  In September this year iSonea launched the AirSonea wheeze monitoring device, its flagship product for asthmatics. The company has attracted business identity Bruce Mathieson as a cornerstone investor.

Adelaide-based drug developer Bionomics progressed a number of its programs targeting renal cancer, depression and anxiety as well as announcing a new partnership with Merck & Co targeting chronic pain. Bionomics had one of the most impressive increases in market cap in the sector, jumping $180m to finish the calendar year at $311m.

“These companies are well-known to those in the sector but are flying somewhat under the radar in the broader market,” commented Mr McNamara.

“Speculation is always there at this time of year regarding the potential for a breakout in the biotech sector. 2013 might go down as the year it turned the corner as we expect a strong year again for the sector in 2014 with product pipelines moving closer to commercialisation and a number of big pharma licensing deals.”

BioScience Managers Fund I remained in the top decile of Global PE/VC funds for FY2013, continuing to deliver a 26%+ net annual IRR and having returned $46 million as it enters its sixth year. Fund II has made six investments to date in AmpliPhi Biosciences Corp, Avita Medical , Nexus6 (NZ), Nexvet Biopharma, SeaDragon (NZ) and Rex Bionics (NZ) .

Phages & the Superbugs War
A specialist team of scientists from the University of Leicester has isolated viruses that eat bacteria - called phages - to specifically target the highly infectious hospital superbug Clostridium difficile (C. diff).

The future impact of antibiotics is dwindling at a pace that no one anticipated, with more and more bacteria out-smarting and 'out-evolving' these miracle drugs. This has re-energized the search for new treatments.

"One alternative to antibiotics is bacteriophages, known as phages, which unlike antibiotics, are specific in what they kill and will generally only infect one particular species, or even strain of bacteria, referred to as the 'host'. Following attachment to their hosts, they inject their DNA into the bacterium, which then replicates many times over, ultimately causing the bacterial cell to burst open. The phages released from the dead bacterium can then infect other host cells."

Dr. Clokie and her team have achieved the remarkable feat of isolating and characterizing the largest known set of distinct C. diff phages that infect clinically relevant strains of C. diff. Of these, a specific mixture of phages have been proved, through extensive laboratory testing, to be effective against 90% of the most clinically relevant C. diff strains currently seen in the U.K.

As a testament to their therapeutic potential, these phages, that are the subject of a patent application, have been licensed by AmpliPhi Biosciences Corporation, a US-based biopharmaceutical company and pioneers in developing phage-based therapeutics. AmpliPhi have already made progress in developing phages targeted against Pseudomonas aeruginosa, a pathogen that causes acute, life-threatening lung infections in cystic fibrosis patients. They were also the first biopharmaceutical company to demonstrate the effectiveness of Pseudomonas phages in controlled and regulated human clinical trials.

NYSE Listing coming - NOTICE OF SPECIAL MEETING OF SHAREHOLDER, Tuesday, February 11, 2014

Volume up significantly today and positive based on the pending NYSE and upcoming shareholder special meeting. Just with the announcement Ampliphi is already getting the Streets attention. Phil Young is doing a tremendous job as CEO since coming aboard in building shareholder value, raising awareness, partnering and this is just the beginning. Brought an approx. $5 mil. market cap company on the Pink Sheets a couple years ago to a $100 mil. plus market cap company with key partnerships. APHB's largest shareholder Intrexon is one of the hottest stocks on the NASDAQ in 2014.

1. PROPOSAL FOR APPROVAL OF MERGER AGREEMENT AND REINCORPORATION FROM WASHINGTON TO DELAWARE.
2. PROPOSAL FOR AUTHORIZATION OF THE REVERSE STOCK SPLIT.
3. PROPOSAL TO ENTER INTO THE INDEMNIFICATION AGREEMENTS.
4. PROPOSAL TO ADOPT AND ASSUME THE STOCK INCENTIVE PLAN

uk.news.yahoo.com/...-risk-real-experts-042134071.html#BhxLp30

mfg

uniQure to pay APHB up to $4.9 in milestones, $100k annual fee, low single digital % net sales Royalties, FDA filing

Excerpt from uniQure's IPO SEC filing. APHB royalty stream to commence in first half of 2014 in EU. Also great new, they'll file an Investigational New Drug application, or IND, with the FDA for Glybera in the first half of 2014

We have to date paid to AmpliPhi a one-time up-front payment of $1,750,000. We have agreed to pay AmpliPhi annual fees of $100,000, a total of $4,950,000 in development and regulatory milestone payments, and a royalty equal to a low single-digit percentage of net sales, if any, of licensed products sold by us or Chiesi.

We met with the Food and Drug Administration, or FDA, to discuss the regulatory pathway for Glybera in the United States, We plan to file an Investigational New Drug application, or IND, with the FDA for Glybera in the first half of 2014.

von leytonorientfan



New analyst coverage : $1 price target

New analyst coverage of APHB last night from Roth Capital Partners, with a $1 target price...

I completely agree about the derisked nature of APHB's products, and the faster development timelines, but the valuation is further derisked by APHB's legacy investments/programs, which they don't mention:

"Roth starts AmpliPhi Biosciences at buy
February 13, 2014 by mcapraro ·

Roth Capital Partners has initiated coverage of AmpliPhi Biosciences (OTC:APHB) with a “buy” rating and price target of $1. The stock closed at 59 cents on Wednesday.

AmpliPhi is developing a validated approach, phage, to combat bacterial infections through its laser guided “smart bomb” approach to address this unmet medical need.

Phage are naturally occurring viruses that infect and kill bacteria but are benign and non-infective to eukaryotic human cells. They are abundant in the natural environment. Bacteriophage have been used for over a century throughout parts of the world as a treatment for bacterial infections, but have not been widely commercially developed for this purpose in the Western World due to the heavy reliance on antibiotics.

AmpliPhi is developing several bacteriophage therapies and has the platform in place to develop many more, writes analyst Joseph Pantginis.

“We see compelling value in AmpliPhi currently, namely because its products are early stage,” he said. “However, due to extensive historical use, we believe this is an unusually de-risked early-stage company.”

Mr. Pantginis figures the development programs at AmpliPhi could be accelerated due to both the unmet medical need and potentially faster development timelines. “We also believe that as the product candidates move forward the partnering potential is high,” he added."

gain good find/posting & great news for APHB shareholders. More to come.

I too agree 100% with your comment that analysts have yet to quantify the value of the legacy assets, especially Glybera since revenue and milestone payments start revenue flowing into APHB mid year 2014. I believe Roth would of at least doubled their price target if they knew this de-risked company had royalties and milestones coming in this year and for the foreseeable future.

The pending NYSE listing in Q.1 (expected) will have Buy Analysts lining up similar to Roth, and I expect with significantly higher price targets.

I too don't think the market and analysts haven't yet understood the significant upside valuation associated with APHB collaboration with Unilever PLC (NYSE: UL) to exploit novel genomic information to develop next generation, specific, natural antimicrobials for use in the personal care industry. Even though it's an early stage development effort, Unilever is a UK/Dutch based $110 billion market cap. multinational

pressekonferenz montag 4.3.2014

mfg

Summary of last night's presentation

Excellent 20 minute presentation by the CEO last night - he stated that 2014 is a "major year" for APHB, and there will be "multiple value-driving events coming up this year".

Main points:

- APHB are "by far the leader in the world in developing bacteriophage"
- APHB have had "positive feedback" from both the FDA re the US Army programme for Staph.aureus and the MHRA re the pseudomonas programme

For 2014:

- 001 : this is the lead programme re pseudomonas and CF patients. A Phase 1 study will be initiated this year in the UK
- 002 : Staph.aureus/MRSA with the US Army. An in-human study will be initiated in Q3/Q4
- 004 : C.diff - data will be reported in the next few quarters

Endorsements/partnerships are ongoing with:

- Intrexon (working with APHB's R&D dept)
- University of Leicester in the UK
- Prince Charles Hospital, Brisbane
- Royal Brompton Hospital in the UK
- Institute Pasteur in Paris
- US Army (at Walter Reed Medical Centre)

The extensive patent portfolio covers:

- phages containing therapeutic agents
- sequential use of phage to enhance subsequent antibiotic application
- formulation and delivery

p25162 • Mar 10, 2014 9:44 PM

   3 users liked this posts users disliked this posts 0
   Reply

$20 Billion addressable market for Ampliphi's initial 3 Phage programs - NYSE listing soon

Impressive presentation by CEO Phil Young today at the 26th Annual ROTH Conference. It was well received by institutional investors/analysts. I recommend listening and viewing the webcast presentation link at their website. "2014 transformational year: multiple valuation driving milestones."

Agreed - NYSE listing coming up before 30th June it seems, plus lots of further news flow this year per slides 23 and 12, with:

P001 - phase 1/2a study initiated in H2'14 with data in H1'15
P002 - initiate phase 1 study in H2'14
P004 - non-clinical proof of date in H2'14

amongst others:

wsw.com/webcast/roth28/aphb/

p25162 • 20 hours ago

   1 users liked this posts users disliked this posts 0
   Reply

RA Capital Management ($850 mil. fund)- loaded up on APHB - recent 13G filing

RA Capital Management, LLC – 26,785,712 shares = 9.9% ownership
Peter Kolchinsky – 26,785,712 shares = 9.9% ownership
RA Capital Healthcare Fund, L.P. – 21,428,575 shares = 7.9% ownership

RA Capital manages approximately $850 mil. The clearly like what they see with Ampliphi. I especially like the fact that Peter K. took a personal (individual) stake as well in Ampliphi with a 9.9% stake.

Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA Capital. In 2002 he broke even when the S&P 500 index lost 22%. By the end of 2003, the initial $4 Million investment became $13 Million. Boston-based RA Capital invests in companies with promising drugs and technologies.

   ce259 • Apr 5, 2014 12:32 AM
       0 users liked this posts users disliked this posts 0
       Reply
   10-K

   The Company intends to file the 2013 10-K by April 15, 2014,
   Hopefully this will start the upward trend toward $1

This is one of the challenges from transitioning to SEC full reporting (disclosure) company and moving to the NYSE. Bottom line APHB's audit team caught the complex Derivatives and Hedging issue dealing with estimated fair value of the derivative instruments that should be recorded as non-cash income or expense in the statement of operations.

Most important point, the non-cash adjustments to the financial statements as of September 30, 2013, do not impact the amounts previously reported for the Company's cash and cash equivalents, operating expenses, or total operating, investing or financing cash flows. No material impact.

Billionaire, CEO of Intrexon Randal Kirk, SEC 13G filing (2-14-15) owns 67.6% of APHB

Randal Kirk (CEO of Intrexon) has a track record of significant investment returns for himself and investors that follow. Based on last weeks 13G filing, Mr. Kirk, Third Security, NRM VII Holdings and Intrexon (all controlled by Kirk), own 67.6% of AmpliPhi. Randal didn't buy all these APHB shares as a tax write off.

e.g. Randal recently purchased an additionally 555k Intrexon (XON) shares in a secondary at $27. Stock closed at $39.30, equating to approx. $7 mil. return in less a month. Plus he already owned 61 mil. shares of Intrexon.

Gestern wieder 2.600.000 stk. Irgendwas läuft da?!

It looks like we are a few short days or weeks from the beginning of a very interesting timeline for shareholders.

AmpliPhage-002: S. aureus (MRSA)
• IND Enabling Preclinical Studies Q2 2015
• cGMP Product Release Q2 2015
• IND Filing Q3 2015
• Phase 1 Clinical Study FPFV Q4 2015
AmpliPhage-001: P. aeruginosa Cystic Fibrosis
• Product qualification Q2 2015
• cGMP Product Manufacturing Q3 2015
• Nebulizer Qualification Q4 2015
• Inhalation Toxicology Q4 2015
AmpliPhage-004: C. difficile(CDI/ CDAD)
• Preclinical efficacy data Q2 2015
• Product qualification Q4 2015

Next 90 days

Events in the next 90 days;
IND Enabling Preclinical Studies for MRSA and cGMP Product Release
Cystic Fibrosis product qualification
C. difficile (CDI/ CDAD) preclinical efficacy data

hoch bei 0,30$

Bis jetzt!!

war nicht normal! bin in der Aktie schon lange drinn, war immer sehr volatil. otc halt. aber so wie gestern war schon lange nicht.

mfg  

toegar2000 yahoo



AmpliPhi Granted European Patent for Bacteriophage Therapy to Fight Biofilm-related Bacterial Infections!!!
This should rocket upward big time today! Good luck longs.

@

OTC Markets Group Congratulates AmpliPhi Biosciences on NYSE MKT Listing